Madrigal Stock Based Compensation To Revenue from 2010 to 2024
| MDGL Stock | USD 345.18 2.27 0.65% |
Stock Based Compensation To Revenue | First Reported 2010-12-31 | Previous Quarter 20.34 | Current Value 21.36 | Quarterly Volatility 6.65484348 |
Check Madrigal Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Madrigal Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 13.3 M, Other Operating Expenses of 399.5 M or Research Development of 286 M, as well as many indicators such as Price To Sales Ratio of 3.4 K, Dividend Yield of 0.0073 or PTB Ratio of 11.2. Madrigal financial statements analysis is a perfect complement when working with Madrigal Pharmaceuticals Valuation or Volatility modules.
Madrigal | Stock Based Compensation To Revenue |
Latest Madrigal Pharmaceuticals' Stock Based Compensation To Revenue Growth Pattern
Below is the plot of the Stock Based Compensation To Revenue of Madrigal Pharmaceuticals over the last few years. It is a metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards. Madrigal Pharmaceuticals' Stock Based Compensation To Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Madrigal Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Stock Based Compensation To Revenue | 10 Years Trend |
|
Stock Based Compensation To Revenue |
| Timeline |
Madrigal Stock Based Compensation To Revenue Regression Statistics
| Arithmetic Mean | 19.87 | |
| Geometric Mean | 15.95 | |
| Coefficient Of Variation | 33.50 | |
| Mean Deviation | 4.27 | |
| Median | 22.60 | |
| Standard Deviation | 6.65 | |
| Sample Variance | 44.29 | |
| Range | 22.1564 | |
| R-Value | 0.52 | |
| Mean Square Error | 34.65 | |
| R-Squared | 0.27 | |
| Significance | 0.05 | |
| Slope | 0.78 | |
| Total Sum of Squares | 620.02 |
Madrigal Stock Based Compensation To Revenue History
About Madrigal Pharmaceuticals Financial Statements
Madrigal Pharmaceuticals investors utilize fundamental indicators, such as Stock Based Compensation To Revenue, to predict how Madrigal Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Stock Based Compensation To Revenue | 20.34 | 21.36 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Madrigal Pharmaceuticals Correlation against competitors. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.02) | Revenue Per Share 3.705 | Return On Assets (0.52) | Return On Equity (1.30) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.